CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison
Tóm tắt
CD19-directed chimeric antigen receptor (CAR) T-cell treatment has evolved as standard of care (SOC) for multiply relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, its potential benefit over allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. We compared outcomes with both types of cellular immunotherapy (CI) by intention to treat (ITT). Eligble were all patients with R/R LBCL and institutional tumor board decision recommending SOC CAR T-cell treatment between July 2018 and February 2020, or alloHCT between January 2004 and February 2020. Primary end point was overall survival (OS) from indication. Altogether, 41 and 60 patients for whom CAR T cells and alloHCT were intended, respectively, were included. In both cohorts, virtually all patients had active disease at indication. CI was recommended as part of second-line therapy for 21 alloHCT patients but no CAR T-cell patients. Median OS from indication was 475 days with CAR T cells vs 285 days with alloHCT (P = .88) and 222 days for 39 patients for whom alloHCT beyond second line was recommended (P = .08). Of CAR T-cell and alloHCT patients, 73% and 65%, respectively, proceeded to CI. After CI, 12-month estimates for nonrelapse mortality, relapse incidence, progression-free survival, and OS for CAR T cells vs alloHCT were 3% vs 21% (P = .04), 59% vs 44% (P = .12), 39% vs 33% (P = .97), and 68% vs 54% (P = .32), respectively. In conclusion, CAR T-cell outcomes were not inferior to alloHCT outcomes, whether measured by ITT or from CI administration, supporting strategies preferring CAR T cells over alloHCT as first CI for multiply R/R LBCL.
Tài liệu tham khảo
Van Den Neste, 2016, Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study, Bone Marrow Transplant, 51, 51, 10.1038/bmt.2015.213
Crump, 2017, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588], Blood, 130, 1800, 10.1182/blood-2017-03-769620
González-Barca, 2020, Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT), Bone Marrow Transplant, 55, 393, 10.1038/s41409-019-0650-x
Epperla, 2019, Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation, Blood Adv, 3, 1661, 10.1182/bloodadvances.2019000102
Tilly, 2015, Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v116, 10.1093/annonc/mdv304
Fenske, 2016, Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation, Br J Haematol, 174, 235, 10.1111/bjh.14046
Kyriakou, 2019, The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin’s lymphoma: a retrospective study by the EBMT Lymphoma Working Party, Biol Blood Marrow Transplant, 25, 86, 10.1016/j.bbmt.2018.08.025
Shah, 2018, Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis, Blood Adv, 2, 933, 10.1182/bloodadvances.2018018531
Urbano-Ispizua, 2015, The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen, Biol Blood Marrow Transplant, 21, 1746, 10.1016/j.bbmt.2015.05.010
Glass, 2014, Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial, Lancet Oncol, 15, 757, 10.1016/S1470-2045(14)70161-5
Robinson, 2016, Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party, Bone Marrow Transplant, 51, 365, 10.1038/bmt.2015.286
Selberg, The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis [published online ahead of print on 18 June 2020], Bone Marrow Transplant
Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447
Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980
Nastoupil, 2020, Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium, J Clin Oncol, 38, 3119, 10.1200/JCO.19.02104
Jacobson, 2020, Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity, J Clin Oncol, 38, 3095, 10.1200/JCO.19.02103
Chow, 2018, Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma, Blood, 132, 777, 10.1182/blood-2018-04-839217
Jain, 2019, Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy, Biol Blood Marrow Transplant, 25, 2305, 10.1016/j.bbmt.2019.08.015
Dreger, 2020, Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?, Biol Blood Marrow Transplant, 26, e77, 10.1016/j.bbmt.2019.12.771
Hamlin, 2003, Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma, Blood, 102, 1989, 10.1182/blood-2002-12-3837
Ziepert, 2010, Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 2373, 10.1200/JCO.2009.26.2493
Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004
Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/S1470-2045(18)30864-7
Schmitz, 2012, Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1), Lancet Oncol, 13, 1250, 10.1016/S1470-2045(12)70481-3
Schmitz, 2015, Allogeneic or autologous transplantation as firstline therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial, J Clin Oncol., 33
Bacigalupo, 2009, Defining the intensity of conditioning regimens: working definitions, Biol Blood Marrow Transplant, 15, 1628, 10.1016/j.bbmt.2009.07.004
Hahn, 2015, Allogeneic hematopoietic stem cell transplantation for poor-risk chronic lymphocytic leukemia: dissecting immune-modulating strategies for disease eradication and treatment of relapse, Bone Marrow Transplant, 50, 1279, 10.1038/bmt.2015.150
Zeisbrich, 2017, Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD, Bone Marrow Transplant, 52, 1399, 10.1038/bmt.2017.119
Schubert, 2020, Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 26, 1575, 10.1016/j.bbmt.2020.04.025
Sermer, 2020, Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies, Blood Adv, 4, 4669, 10.1182/bloodadvances.2020002118
Pinnix, 2020, Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma, Blood Adv, 4, 2871, 10.1182/bloodadvances.2020001837
Shah, 2019, Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis, Blood Cancer J, 9, 97, 10.1038/s41408-019-0261-1
Duarte, 2019, Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019, Bone Marrow Transplant, 54, 1525, 10.1038/s41409-019-0516-2
Chow, 2019, Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy, Am J Hematol, 94, E209, 10.1002/ajh.25505
Ram, 2011, Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 17, 1537, 10.1016/j.bbmt.2011.03.010
Wudhikarn, 2011, Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome, Biol Blood Marrow Transplant, 17, 1497, 10.1016/j.bbmt.2011.02.009
Shadman, 2019, Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy, Blood Adv, 3, 3062, 10.1182/bloodadvances.2019000593
Ramos, 2018, In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas, Mol Ther, 26, 2727, 10.1016/j.ymthe.2018.09.009
Schubert, 2019
Wang, 2020, Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies, Blood, 135, 17, 10.1182/blood.2019000017
Costa, 2017, Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies, Am J Hematol, 92, 161, 10.1002/ajh.24615
Bishop, 2019, Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion, Blood Adv, 3, 2230, 10.1182/bloodadvances.2019000151